0001448431-26-000011
SEC filingQ1 revenue declined 9.5% year-over-year to $19.8M following exit from a low-margin managed service program, offset by 11.9% gross profit growth to $14.9M at 75.2% margin and first operating profit of $396K from efficiency initiatives.
Revenue of $19.8 million decreased 9.5% from $21.9 million in Q1 FY2025, primarily attributable to the conclusion of a low-margin managed service program in Q3 2025. This shift has allowed focus on higher-margin solutions like DAAP, which inherently offer better profitability than other messaging solutions. The percent of total revenue from top 20 pharmaceutical manufacturers declined, reflecting year-over-year decreases from those customers alongside growth from non-top 20 sources. Net revenue retention also declined due to lower DTC-related managed service revenue and reduced top-20 pharma contributions, though the master service agreement with a key customer remains in effect with uncertain future revenue.
Gross profit rose 11.9% to $14.9 million, expanding the margin to 75.2% from prior levels. This improvement stems from the strategic pivot away from low-margin programs toward higher-margin pharma messaging, enhancing overall product mix efficiency. Operating income swung to a $396 thousand profit from a $2.1 million loss, representing a 118.7% improvement. This was primarily a result of cost savings realized across various expense categories through ongoing efficiency initiatives, delivering the company's first quarterly operating profitability and supporting a 2.0% operating margin.
Net income narrowed to a $495 thousand loss from $2.2 million, a 77.5% reduction, with diluted EPS improving to -$0.03 from -$0.12. These gains reflect the operating leverage from margin expansion and cost controls, despite ongoing interest expenses.
Management's strategy emphasizes revenue growth through higher-margin drivers like DAAP, working in tandem with efficiency efforts to boost profitability. While top-20 pharma declines and customer concentration introduce risks, the focus on premium solutions positions OptimizeRx for sustained operating profits as topline stabilizes. A material weakness in third-party data controls persists but was addressed via additional procedures for this filing.